X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6527) 6527
Publication (485) 485
Book Review (96) 96
Book Chapter (40) 40
Newsletter (40) 40
Magazine Article (25) 25
Conference Proceeding (14) 14
Dissertation (5) 5
Book / eBook (1) 1
Paper (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3663) 3663
index medicus (2528) 2528
lactones - therapeutic use (2353) 2353
animals (2331) 2331
male (1754) 1754
pharmacology & pharmacy (1619) 1619
female (1563) 1563
lactones - pharmacology (1298) 1298
lactones (995) 995
mice (807) 807
adult (761) 761
middle aged (757) 757
chemistry, medicinal (753) 753
lactones - adverse effects (747) 747
lactones - chemistry (667) 667
rats (619) 619
sesquiterpene lactones (567) 567
anti-obesity agents - therapeutic use (557) 557
analysis (555) 555
sulfones (506) 506
aged (504) 504
lactones - administration & dosage (494) 494
obesity - drug therapy (481) 481
biochemistry & molecular biology (442) 442
cancer (434) 434
cyclooxygenase inhibitors - therapeutic use (432) 432
apoptosis (425) 425
dose-response relationship, drug (420) 420
research (412) 412
treatment outcome (410) 410
orlistat (409) 409
anti-inflammatory agents, non-steroidal - therapeutic use (402) 402
celecoxib (397) 397
rofecoxib (383) 383
cell line, tumor (373) 373
sesquiterpenes - pharmacology (357) 357
oncology (344) 344
plant extracts - pharmacology (339) 339
ivermectin (338) 338
plant sciences (333) 333
obesity (323) 323
expression (322) 322
sulfones - therapeutic use (319) 319
inhibition (310) 310
care and treatment (303) 303
health aspects (303) 303
in-vitro (300) 300
double-blind method (296) 296
nonsteroidal antiinflammatory drugs (291) 291
time factors (280) 280
anti-inflammatory agents, non-steroidal - adverse effects (279) 279
drugs (278) 278
cyclooxygenase inhibitors - adverse effects (277) 277
microbiology (268) 268
risk factors (267) 267
apoptosis - drug effects (265) 265
molecular structure (261) 261
inflammation (260) 260
medicine, general & internal (259) 259
article (257) 257
cyclooxygenase 2 (253) 253
structure-activity relationship (250) 250
sulfones - adverse effects (248) 248
quorum sensing (247) 247
antineoplastic agents - pharmacology (242) 242
sulfonamides - therapeutic use (242) 242
parasitology (239) 239
weight loss (239) 239
adolescent (237) 237
chemistry, organic (237) 237
cyclooxygenase 2 inhibitors (236) 236
nf-kappa-b (236) 236
physiological aspects (235) 235
chemistry, multidisciplinary (222) 222
cell proliferation - drug effects (220) 220
drug therapy (220) 220
membrane proteins (219) 219
cells (218) 218
bacteria (215) 215
research article (211) 211
drug resistance (210) 210
rheumatoid-arthritis (208) 208
cell survival - drug effects (207) 207
proteins (205) 205
clinical trials as topic (204) 204
cyclobutanes - therapeutic use (204) 204
macrolides (204) 204
toxicology (204) 204
medicine (203) 203
rats, sprague-dawley (202) 202
disease models, animal (201) 201
phytotherapy (199) 199
enzymes (198) 198
immunology (198) 198
plant extracts - therapeutic use (197) 197
pyrazoles (197) 197
activation (196) 196
anthelmintics - therapeutic use (195) 195
lactone (195) 195
integrative & complementary medicine (193) 193
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6116) 6116
German (265) 265
French (57) 57
Russian (30) 30
Chinese (29) 29
Japanese (29) 29
Spanish (25) 25
Italian (14) 14
Polish (9) 9
Swedish (6) 6
Danish (5) 5
Finnish (5) 5
Hungarian (5) 5
Czech (4) 4
Dutch (4) 4
Norwegian (3) 3
Turkish (3) 3
Hebrew (2) 2
Serbian (2) 2
Bulgarian (1) 1
Croatian (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


American Heart Journal, ISSN 0002-8703, 2014, Volume 168, Issue 5, pp. 611 - 621
Mortality and morbidity in acute coronary syndromes (ACSs), caused principally by plaque erosion or rupture leading to thrombus formation and myocardial... 
Cardiovascular | WORKING GROUP | CARDIAC & CARDIOVASCULAR SYSTEMS | ANTITHROMBOTIC THERAPY | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | EUROPEAN-SOCIETY | ELEVATION MYOCARDIAL-INFARCTION | CONSENSUS DOCUMENT | PLATELET REACTIVITY | ATRIAL-FIBRILLATION | UNFRACTIONATED HEPARIN | Recombinant Proteins - therapeutic use | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Hirudins | Humans | Heparin - therapeutic use | Enoxaparin - therapeutic use | Tyrosine - analogs & derivatives | Receptors, Thrombin - antagonists & inhibitors | Warfarin - therapeutic use | Tyrosine - therapeutic use | Adenosine - therapeutic use | Aspirin - therapeutic use | Drug Therapy, Combination | Platelet Aggregation Inhibitors - therapeutic use | Purinergic P2Y Receptor Antagonists - therapeutic use | Pyridines - therapeutic use | Polysaccharides - therapeutic use | Anticoagulants - therapeutic use | Piperazines - therapeutic use | Adenosine Monophosphate - therapeutic use | Lactones - therapeutic use | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Adenosine Monophosphate - analogs & derivatives | Peptide Fragments - therapeutic use | Peptides - therapeutic use | Aspirin | Glycosaminoglycans | Atrial fibrillation | Mortality | Thrombin | Anticoagulants (Medicine) | Health aspects | Drug approval | Coronary heart disease | Heart attacks | Acute coronary syndromes | Drug therapy | Clinical outcomes | Kardiologi | Clinical Medicine | Cardiac and Cardiovascular Systems | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap
Journal Article
Journal Article
2018, ISBN 0444640568, Volume 58
Many plants containing terpenoids are used in traditional medicine for their pain-relieving and antiinflammatory properties. A well-known example is... 
Migraine prophylactic | Terpenoid | Parthenolide | Sesquiterpene lactone | Anticancer activity
Book Chapter
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 02/2018, Volume 2018, Issue 2, p. CD004121
Background This is an updated version of the original Cochrane review published in 2014, Issue 4. Cervical intraepithelial neoplasia (CIN) precedes the... 
COX-2 | Sulfones [administration & dosage; therapeutic use] | Humans | Sulfonamides [administration & dosage; therapeutic use] | COLON-CANCER | MEDICINE, GENERAL & INTERNAL | PHASE-II TRIAL | CHEMOPREVENTIVE ACTIVITY | TRANSITIONAL-CELL CARCINOMA | Pyrazoles [administration & dosage; therapeutic use] | Female | Lactones [administration & dosage; therapeutic use] | INHIBITOR | UP-REGULATION | Uterine Cervical Neoplasms [drug therapy] | Administration, Oral | Induction Chemotherapy [methods] | Celecoxib | Disease Progression | Randomized Controlled Trials as Topic | DOUBLE-BLIND | Cyclooxygenase 2 Inhibitors [administration & dosage; therapeutic use] | CYCLOOXYGENASE-2 EXPRESSION | Anti-Inflammatory Agents, Non-Steroidal [administration & dosage; therapeutic use] | Cervical Intraepithelial Neoplasia [drug therapy] | Sulfones - therapeutic use | Cervical Intraepithelial Neoplasia - pathology | Cyclooxygenase 2 Inhibitors - administration & dosage | Induction Chemotherapy - methods | Cervical Intraepithelial Neoplasia - drug therapy | Uterine Cervical Neoplasms - drug therapy | Uterine Cervical Neoplasms - pathology | Celecoxib - therapeutic use | Lactones - therapeutic use | Placebos - therapeutic use | Sulfonamides - therapeutic use | Anti-Inflammatory Agents, Non-Steroidal - therapeutic use | Lactones - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - administration & dosage | Cyclooxygenase 2 Inhibitors - therapeutic use | Adult | Sulfonamides - administration & dosage | Sulfones - administration & dosage
Journal Article
Journal Article
Gastroenterology, ISSN 0016-5085, 2017, Volume 152, Issue 7, pp. 1765 - 1779
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2008, Volume 35, Issue 3, pp. 255 - 261
Summary Drugs that affect microtubule dynamics, including the taxanes and vinca alkaloids, have been a mainstay in the treatment of leukemias and solid tumors... 
Hematology, Oncology and Palliative Medicine | 2-Methoxyestradiol | Discodermolide | Microtubule-targeting agent | Epothilone | Halichondrin B | Microtubule | Taxane | Colchicine | Vinca alkaloid | Taccalonolide | BETA-TUBULIN | VASCULAR DISRUPTING AGENTS | SOLID TUMORS | ANTITUMOR-ACTIVITY | EVERY 28 DAYS | COMBRETASTATIN A4 PHOSPHATE | CELL LUNG-CANCER | BREAST-CANCER | STABILIZING AGENTS | ONCOLOGY | PHASE-I | Colchicine - pharmacology | Taxoids - pharmacology | Tubulin Modulators - pharmacology | Colchicine - therapeutic use | Humans | Epothilones - pharmacology | Epothilones - therapeutic use | Lactones - pharmacology | Drug Delivery Systems | Taxoids - therapeutic use | Neoplasms - genetics | Bridged Bicyclo Compounds, Heterocyclic - therapeutic use | Microtubules - drug effects | Vinca Alkaloids - pharmacology | Microtubules - ultrastructure | Macrolides - pharmacology | Steroids - pharmacology | Steroids - therapeutic use | Antineoplastic Agents, Phytogenic - therapeutic use | Microtubules - physiology | Clinical Trials as Topic | Vinca Alkaloids - therapeutic use | Cell Division - drug effects | Lactones - therapeutic use | Tubulin Modulators - therapeutic use | Neoplasms - drug therapy | Bridged Bicyclo Compounds, Heterocyclic - pharmacology | Animals | Antineoplastic Agents, Phytogenic - pharmacology | Macrolides - therapeutic use | Neoplasms - pathology | Drug Screening Assays, Antitumor | Development and progression | Care and treatment | Leukemia | Analysis | Cancer | Index Medicus | Microtubule-Targeting Agent | Vinca Alkyloid
Journal Article